Serum metabolomic profile of myasthenia gravis and potential values as biomarkers in disease monitoring
Authors:
Open Access
- 15 July 2024
- journal article
- research article
- Published by Elsevier in Clinica Chimica Acta
- Vol. 562, 119873
Abstract
No abstract availableKeywords
This publication has 36 references indexed in Scilit:
- What Is Myasthenia Gravis?JAMA, 2024
- Review of Metabolomics-Based Biomarker Research for Parkinson’s DiseaseMolecular Neurobiology, 2021
- Proteomic and Metabolomic Characterization of COVID-19 Patient SeraCell, 2020
- Impact of β-glycerophosphate on the bioenergetic profile of vascular smooth muscle cellsJournal of Molecular Medicine, 2020
- Beyond the antibodies: serum metabolomic profiling of myasthenia gravisMetabolomics, 2019
- Metabolomics and Lipidomics of Ischemic Stroke2018
- Frontiers of high-throughput metabolomicsCurrent Opinion in Chemical Biology, 2017
- Cessation of biomechanical stretch model of C2C12 cells models myocyte atrophy and anaplerotic changes in metabolism using non-targeted metabolomics analysisThe International Journal of Biochemistry & Cell Biology, 2016
- Does change in acetylcholine receptor antibody level correlate with clinical change in myasthenia gravis?Muscle & Nerve, 2014
- Comparison of muscle ultrastructure in myasthenia gravis with anti-MuSK and anti-AChR antibodiesJournal of Neurology, 2010